US Rescheduling Opens IPO and Private Funding Opportunities for Cannabis-Based Drug Companies

The rescheduling of cannabis in the United States could increase initial public offering (IPO) and private investment opportunities for companies developing cannabis-based drugs. This regulatory change facilitates access to capital markets for sector companies, supporting their growth potential. According to Reuters, firms working on cannabis-based drugs expect a rise in investor interest after the U.S. Drug Enforcement Administration (DEA) moved cannabis to a less restrictive category. This rescheduling may allow companies to accelerate research and development activities and bring new products to market. In particular, a clearer roadmap for FDA approval of cannabis-based drugs could positively impact the valuation of companies in this field. With reduced regulatory uncertainty, investors are becoming more willing to allocate capital to the sector. Experts predict that the rescheduling will trigger not only IPOs but also private equity and venture capital investments. This could lower financing costs for cannabis-based drug developers and accelerate innovation in the sector. This is not investment advice.